Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Stock Information for Intensity Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.